News and Events
Stay informed about RECOVER’s Long COVID research by reading the latest news and participating in upcoming events.

Stay informed about RECOVER’s Long COVID research by reading the latest news and participating in upcoming events.

NIH and FNIH leaders will share insights and answer questions about the progress being made on the first wave of RECOVER-TLC clinical trials.
Researchers at 17 study sites across the US will test a possible treatment to help improve thinking and memory problems and reduce fatigue for people who have Long COVID.
Recent RECOVER publications include findings about possible causes of and treatments for Long COVID.
Results from the RECOVER-AUTONOMIC Moderate POTS (Ivabradine) clinical trial will be presented at an upcoming session of the American College of Cardiology (ACC) Annual Conference on March 28, 2026.
A public comment period will allow patients, caregivers, and researchers to comment on a study to test whether stellate ganglion nerve block (SGB) can help improve Long COVID symptoms.
RECOVER marks 5 years of Long COVID research, with NIH leaders, scientists, and clinicians continuing to guide and advance the initiative’s mission. In 2026, RECOVER will expand clinical trials to find answers for the Long COVID community.
While recruiting potential participants for its clinical trials focused on sleep disturbances, RECOVER study teams also conducted additional health screenings to identify and treat individuals with a sleep condition called sleep apnea.
In 2025, RECOVER’s progress included closing the first phase of its adult observational study and publishing its first clinical trial results. This year, the initiative continues its studies and sharing research findings.